Abstract B and T lymphocyte attenuator (BTLA) is a lymphocyte inhibitory receptor mainly expressed on several subsets of T and B lymphocytes. In the current retrospective study, BTLA expression is examined for the first time on formalin fixed and paraffin embedded (FFPE) tissue sections of mature B cell non-Hodgkin's lymphomas (253 cases), using a newly developed monoclonal antibody. BTLA is highly expressed in chronic lymphocytic leukemia/small lymphocytic lymphoma. In contrast, BTLA expression is nearly absent in mantle cell lymphoma and is not expressed in any of the follicular lymphoma cases of all grades. In marginal zone lymphoma, diffuse large B cell lymphoma, and Burkitt's lymphoma, a minority of the cases exhibit expression of BTLA. This study demonstrates the value of BTLA expression as an additional tool in the panel of immunochemical markers used for the differential diagnosis of mature B cell lymphomas in FFPE tissue sections.
Introduction
B and T lymphocyte attenuator (BTLA) (CD272) is a transmembrane glycoprotein, acting as a negative regulator of lymphocyte activation. BTLA is a member of the CD28-like immune regulators family that takes part in the coordination of immune responses through the T cell receptor (TCR) and the B cell receptor (BCR)-mediated signaling [1] [2] [3] [4] . BTLA is expressed on anergic CD4+ T cells, subsets of activated T cells, resting and memory B cells, and has a lower expression on macrophages, dendritic cells, and natural killer cells. BTLA expression was not detected in non-immune cells [1, 5, 6] . Other members of the family, such as CD28, programmed cell death protein 1 (PD-1), inducible T cell co-stimulator, and cytotoxic T lymphocyte antigen 4 (CTLA-4), are also co-receptors that serve as either positive or negative effectors of the immune response. A primary costimulatory signal is delivered through the CD28-like receptors after engagement of B7-like family members, which are expressed on antigen-presenting cells and act as their ligands. BTLA exerts its inhibitory signals through interaction with herpesvirus entry mediator (HVEM), a member of the tumor necrosis factor (TNF) superfamily [7, 8] . The binding of BTLA to HVEM induces suppression of responses to self-antigens, thereby preventing autoimmune diseases and regulating responses to non-self molecules in adaptive immunity [3] . In the human reactive lymphoid tissue, BTLA is expressed by subsets of interfollicular T lymphocytes, mostly T regulator cells, by B cells in the mantle and marginal 2zones of the lymphoid follicle and by follicular T helper cells in the germinal center (GC) [9] . The expression of BTLA in human malignant lymphomas was previously described mainly in blood and bone marrow cells [10, 11] as well as in a limited number of cases of fresh lymphoid tissue frozen sections [9] . To the best of our knowledge, our study is the first performed on routine formalin fixed and paraffin embedded (FFPE) sections to analyze BTLA expression by neoplastic B cells in a large group of human mature B cell lymphomas.
Materials and methods

Tissue sampling
A total of 253 FFPE samples from biopsies of mature B cell lymphomas were studied. All the cases were classified according to the last World Health Organization classification (2008) [12] into chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL) of all grades, marginal zone lymphoma (MZL), diffuse large B cell lymphoma (DLBCL) and Burkitt's lymphoma (BL). One hundred thirteen samples were obtained from cases diagnosed between 2001 and 2010, based on morphologic examination and immunophenotyping, and stored at the Tissue Diagnosis and Cancer Research Department in Ha'Emek Medical Center, Afula, Israel. These biopsies were examined using conventional whole FFPE sections. The additional 140 cases were obtained from microarrays representative FFPE tissue core of lymphomas, kindly provided by Dr. Giovanna Roncador, head of the Monoclonal Antibodies Unit, Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spain (see Table 1 for summary of cases). A control group of FFPE non-neoplastic tissues from reactive lymphoid tissue (the tonsil and spleen) showing common features of hyperplasia (n016) was also tested. Control group biopsies were obtained from the Tissue Diagnosis and Cancer Research Department in Ha'Emek Medical Center, Afula, Israel. The study was approved by the institutional ethical committee.
Single immunohistochemical staining
Immunostaining of FFPE sections was performed in an automated stainer (Benchmark; Ventana Systems, Phoenix, AZ, USA). Slide-mounted 2 μm sections were subjected to Tris based buffer antigen retrieval followed by incubation with primary antibody for 32 min. Sections of the reactive tonsils were used as positive control samples, while negative control samples were prepared by using secondary antibody only. Single immunostaining was performed using the new anti-BTLA monoclonal antibody (clone FLO67B, kindly provided by Dr. Giovanna Roncador, CNIO, Madrid, Spain), PAX-5 (clone RM-9133, Thermo Scientific, Waltham, MA, USA), BCL-1 (clone RM-9104, Thermo Scientific, USA), BCL-6 (clone GI 191E/A8, kindly provided by Dr. Giovanna Roncador, CNIO, Madrid, Spain) and CD20 (clone M-0755, Dako, Glostrup, Denmark) antibodies. iVIEW DAB detection kit (760-091, Ventana Systems, USA) was used for reaction detection according to the manufacturer-recommended protocol. Hematoxylin counterstain was used for color development. Pictures of relevant sections were acquired with a DP70 camera on a BX51 microscope (both from Olympus Optical Ltd, Tokyo, Japan).
Double immunohistochemical (double IHC) staining
The selected positively and negatively stained biopsy sections were also studied using two-color immunostaining of BTLA and PAX-5, which was used for BTLA expression in B cells. BTLA/Bcl-6 immunostaining was used for identifying neoplastic B cells in FL and BL, and BTLA/Bcl-1 in MCL. The staining was performed on 2-μm FFPE sections in BenchMark automated stainer with serial use of iView DAB detection kit (760-091, Ventana Systems, USA) which stains brown with DAB reagent and ultraView universal alkaline phosphatase red detection kit (760-501, Ventana Systems, USA) which stains red with fast red. Hematoxylin counterstain was used for color development. 
Results
The pattern of BTLA expression in the reactive lymphoid tissue was studied on the tonsil and spleen sections, as a control group (Fig. 1) . A strong expression of BTLA was localized in the marginal and mantle zone of the reactive follicles around the GC, and few interfollicular cells displayed a weak expression (Fig. 1a, b) . The B cells in the GC did not express BTLA, as confirmed by double IHC with BTLA and Bcl-6 (Fig. 1b) . We found, as well, a similar pattern of BTLA expression in sections of normal spleen (Fig. 1c) . These findings corroborate the previous descriptions of BTLA expression in fresh frozen tissue of reactive lymph nodes [9] .
In the current study, we examined BTLA expression in 253 cases of non-Hodgkin's mature B cell lymphomas including CLL/SLL, MCL, FL, MZL, DLBCL, and BL. All FFPE sections were subjected to single IHC with BTLA CLL/SLL showed a significant difference in frequency of positive vs. negative BTLA staining (52/55 positive cases; χ 2 (1)043.65, p<0.0001). BTLA expression in CLL/SLL is shown in Fig. 2a-c . Of note, a stronger staining of BTLA is commonly seen in the prolymphocytes and paraimmunoblasts of the proliferation center (Fig. 2a inset) . BTLA expression by CLL/SLL cells was confirmed in all CLL/ SLL samples by double staining (Fig. 2b, c) . BTLA expression is absent in almost all but three samples of MCL (3/85 positive cases), showing significant difference in BTLA expression frequency (χ 2 (1)073.42, p<0.0001). The pattern of expression in MCL is displayed in Fig. 2d-f . BTLA expression by the lymphoma B cells was confirmed in the positive cases of MCL by double IF (Fig. 2f) .
Most DLBCL cases (29/35) did not express BTLA (Fig. 3a) . Six cases (17 %) of DLBCL exhibited a faint to strong BTLA labeling of the lymphoma B cells (Fig. 3b, c) . This difference in BTLA expression frequency was shown to be significant (χ 2 (1)015.11, p<0.0001) ( Table 1) . Regarding BL, only 3 out of 18 cases showed strong expression of BTLA (Fig. 3d-g ). BTLA expression by the lymphoma B cells was confirmed by double IHC and double IF in all the BTLA-positive cases of DLBCL (Fig. 3c) and BL (Fig. 3f, g ). Of the 20 cases of MZL, 15 were negative for BTLA expression; however, in five cases the neoplastic B cells expressed BTLA (χ 2 (1)05.0, p00.025) as confirmed by double staining (data not shown). BTLA expression was not detected in any neoplastic cells of the FL samples of all grades (40 cases, data not shown). Summary of results is shown in Table 1 .
Discussion
The current study describes the pattern of expression of BTLA by neoplastic B cells in FFPE sections of human tissue in 253 samples of mature B cell lymphomas, using a recently developed anti-BTLA monoclonal antibody. To the and BTLA (upper right inset) (CD20-red and BTLA-green; original magnification, ×400). d In most of MCL cases, the neoplastic cells are not stained with BTLA, while scattered reactive cells are labeled by BTLA (arrow) (single IHC; original magnification, ×200). e, f The three MCL cases expressing BTLA by single IHC are confirmed by double IF on FFPE sections with co-expression of CD20 and BTLA (e, original magnification, ×200; f, CD20-red and BTLA-green; original magnification, ×400) best of our knowledge, it is the largest study examining BTLA expression in human B cell lymphomas and the first to report about BTLA expression in histopathology routine FFPE biopsy material. Previous findings regarding BTLA expression in lymphocytes were obtained in studies of mice [1, 5, [13] [14] [15] as well as human blood and bone marrow cells [10, 11, 16] . A limited number of human lymphoma fresh frozen tissue sections were also examined [9] . However, the later involved a technique rarely available for the diagnosis of lymphoma in daily practice in most medical centers.
The BTLA-HVEM complex is a key factor in the fine tuning of the immune response. BTLA inhibits the response of T lymphocytes by decreasing proliferation and cytokines production after TCR engagement and its activity is essential to prevent the development of autoimmune disease and for the regulation of the adaptive immunity, including antitumoral response [3, 17, 18] .
The pattern of BTLA activity was extensively studied in T cells, but to a lesser extent in B lymphocytes. BTLA was found to be associated with the BCR complexactivating members IgM and CD79a/b. BTLA attenuates B cells activation by reducing downstream signaling of BCR complex-associated molecules, like spleen tyrosine kinase (Syk) and B cell linker protein, whose phosphorylation was shown to be reduced upon BTLA binding to HVEM after BCR engagement [4] . CLL/SLL is a disease with a highly variable clinical course related to the mutated or unmutated BCR status, among other factors, which corresponds to the pre-or post-GC cell of origin of the neoplasm [19] . The current study confirms the high expression of BTLA in CLL/SLL (Fig. 2) , which is also found by M'hidi et al. [9] . BTLA, as an attenuator of the Syk-related BCR pathway activation, may play an important role in the course of CLL/SLL progression, especially as Syk signaling was found to enhance CLL/SLL neoplastic cells survival, adhesion, and chemotaxis [20] .
The neoplastic B cells of the CLL/SLL were found to coexpress PD-1 along with BTLA, in a very similar pattern [21] . The presence of proliferation centers is one of the histological hallmarks of the disease. In the current study, we observed a stronger expression of BTLA in the paraimmunoblasts and prolymphocytes of the CLL/SLL proliferation centers than in small neoplastic cells (Fig. 2a, inset) , a feature that was also observed in PD-1 expression in CLL/SLL [21] . The simultaneous expression of BTLA and PD-1 has been recently shown to play a critical role in the mechanism responsible for immune escape that causes dysfunction of tumor-specific CD8 (+) T cell [22, 23] . The role of the immune microenvironment is crucial for the response of B neoplastic cells to therapy and for long-term prognosis in mature B cell lymphomas [24] [25] [26] [27] ; For instance, it was shown the gene expression signature of the tumor-infiltrating and immune-reactive cells in FL is more predictive at diagnosis than the tumor cells properties [24, 25] , and has a more crucial impact on the response to therapy than any other factor [26] . Concurrent targeting of BTLA and PD-1 pathways may play a crucial role, especially in preventing tumoral immune escape. It was demonstrated that tumor-specific T cell response can be restored by interference with the BTLA-HVEM pathway in combination with vaccination therapy in melanoma patients [28] .
Finally, our study shows BTLA expression in 17 % of DLBCL cases, as confirmed by double IF (Fig. 3) . DLBCL encompasses a heterogeneous group of diseases sharing the same morphologic features, yet having diverse responses to treatment protocols and overall survival [12, 16] . It is conceivable that the pattern of BTLA expression in DLBCL may distinguish subsets of patients. BCR status in DLBCL, which is related to BTLA function, as previously discussed [4, 29, 30] , has been shown to have a prognostic impact through the Syk pathway.
Our results show a significant difference in the frequency of positive vs. negative BTLA expression in CLL/SLL, MCL, and DLBCL (Table 1) , which indicates that the use of BTLA monoclonal antibody may be beneficial in the antibodies panel utilized for the differential diagnosis in routinely examined FFPE sections of mature B cell lymphomas. Further studies that will include larger number of cases and will relate to other prognostic factors may elucidate BTLA function in B cell lymphomas as a possible marker of specific disease subgroups as well as evaluate the potential use of BTLA as a therapeutic target.
